GemPharmatech Co

GemPharmatech Co Operating Cash Flow

The Operating Cash Flow of GemPharmatech Co (688046.SS) as of Oct 22, 2026 is 227.03 M CNY. In the previous year, Operating Cash Flow was 90.31 M CNY — a change of 151.37% (higher).

Operating Cash Flow

227.03 MCNY

YoY

151.37%

Last updated:

Operating Cash Flow of GemPharmatech Co is 2025 227.03 M CNY. Operating Cash Flow of GemPharmatech Co was 2024 90.31 M CNY. It decreases by 151.37% higher compared to the previous year.

The GemPharmatech Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
43.41 M CNY
Jan 1, 2019
65.12 M CNY
Jan 1, 2020
129.79 M CNY
Jan 1, 2021
113.31 M CNY
Jan 1, 2022
105.98 M CNY
Jan 1, 2023
116.57 M CNY
Jan 1, 2024
90.31 M CNY
Jan 1, 2025
227.03 M CNY
The GemPharmatech Co Operating Cash Flow history
YEAROperating Cash FlowYoY
227.03 MCNY+151.37%
90.31 MCNY-22.52%
116.57 MCNY+9.99%
105.98 MCNY-6.47%
113.31 MCNY-12.69%
129.79 MCNY+99.29%
65.12 MCNY+50.00%
43.41 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Operating Cash Flow of GemPharmatech Co is 227.03 M CNY in 2025.

Operating Cash Flow of GemPharmatech Co changed from 90.31 M CNY to 227.03 M CNY, representing a 151.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GemPharmatech Co

All Key Metrics — GemPharmatech Co